MRI contrast agents market seen reaching $2.17 billion by 2030

The global MRI contrast agents market is projected to rise from $1.64 billion in 2026 to $2.17 billion by 2030, driven by chronic disease growth, better imaging technology and expanding outpatient diagnostics. North America leads today, while Asia-Pacific is expected to grow fastest as healthcare access expands.

Why it matters: - MRI contrast agents help clinicians see tissues more clearly during scans, improving diagnosis of chronic disease and other conditions. - The market outlook signals continued spending on diagnostic imaging as demand rises for earlier and more precise detection. - Download a free sample of the market report for more detail on the forecast.

What happened: - The Business Research Company projected the MRI contrast agents market will grow from $1.53 billion in 2025 to $1.64 billion in 2026. - The report forecast the market will reach $2.17 billion by 2030. - The report said the market is growing at a 7.1% CAGR in the historical period and a 7.4% CAGR in the forecast period. - The report was released July 3, 2026, from London.

The details: - MRI contrast agents are substances that improve the clarity of internal structures in MRI scans by changing the magnetic environment around tissues. - The agents affect the relaxation time of hydrogen nuclei, which changes signal intensity in MRI images. - The result is clearer separation between healthy and abnormal tissue. - The report tied recent growth to higher chronic disease prevalence, better diagnostic imaging infrastructure, rising healthcare spending, expanding hospital networks and ongoing MRI technology innovation. - The report linked future growth to targeted contrast agents, rising demand for precise diagnostic tools, more outpatient imaging facilities, continued formulation advances and greater awareness of early disease detection. - Emerging trends include wider use of gadolinium-based agents, demand for safer and lower-toxicity products, more neurological and gastrointestinal disease cases, nanoparticle-based contrast agent innovation and broader MRI use in diagnostic centers. - Chronic disease growth remains a major demand driver because contrast agents support diagnosis, disease tracking and treatment response evaluation. - Macmillan Cancer Support reported in August 2024 that more than 3 million people in the UK were living with cancer, with that figure expected to rise to 3.5 million by 2025, 4 million by 2030 and 5.3 million by 2040. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covered South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa. - View the full market report for the complete regional and segment analysis.

Between the lines: - The forecast points to a market shifting from broad imaging demand toward more specialized, lower-toxicity and targeted contrast products. - Strong growth in outpatient imaging suggests more scans will move beyond major hospitals into distributed care settings. - North America’s lead reflects existing medical infrastructure, but Asia-Pacific’s projected pace suggests future growth will increasingly come from healthcare expansion rather than mature-market replacement demand.

What's next: - The report expects continued product development around targeted, safer and nanoparticle-based contrast agents. - Market attention will likely stay focused on early detection use cases, outpatient imaging growth and regional expansion in Asia-Pacific. - The Business Research Company said its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and trend graphics.